News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evolva SA Agrees to Reverse Merger with Arpida



9/11/2009 8:43:50 AM

Bookmark and Share

pehub.com -- Evolva SA, a Swiss biotech company that uses a genetic chemistry platform to developer small molecule drugs, has agreed to go public via a reverse merger with Arpida Ltd., which is listed on the Swiss stock exchange (SIX: ARPN). Evolva has raised around $20 million in VC funding from firms like Novartis Venture, Aravis, Sunstone Capital and Dansk Innovationsinvestering. It also says it plans to raise another CHF 25 million from new and existing investors.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES